Exelixis's 15min chart triggered KDJ Golden Cross, Bullish Marubozu signal.

According to the 15-minute chart of Exelixis, a golden cross has occurred on the KDJ indicator, accompanied by a bullish marubozu candlestick pattern at 13:00 on September 3, 2025. This indicates that the momentum of the stock price is shifting towards the upside, and there is potential for further growth. The buyers have taken control of the market, and it is likely that the bullish momentum will continue.

Exelixis, Inc. (NASDAQ: EXEL), a biotechnology company specializing in therapies for difficult-to-treat cancers, experienced a notable technical event on September 3, 2025. According to the 15-minute chart, a golden cross occurred on the KDJ indicator, accompanied by a bullish marubozu candlestick pattern at 13:00. This combination suggests a shift in momentum towards the upside, indicating potential for further growth in the stock price [1].

The golden cross, where the faster moving average crosses above the slower moving average, is a bullish signal in technical analysis. The marubozu candlestick pattern, characterized by no shadows on the candlestick, further reinforces this positive trend. This pattern typically signifies strong buying pressure, suggesting that buyers have taken control of the market [2].

Exelixis, Inc. has been focused on developing and commercializing therapies for advanced renal cell carcinoma and medullary thyroid cancer, with its flagship product CABOMETYX (cabozantinib) driving growth in these areas. The company has also maintained a robust oncology pipeline, including candidates such as zanzalintinib and XL309. Despite recent revenue reports slightly below expectations for CABOMETYX, contributing to a modest stock decline, the company's pipeline development remains a key focus [1].

The company's decision not to pursue the Phase 3 portion of the STELLAR-305 trial for squamous cell carcinoma, opting instead for more commercially promising opportunities, reflects a strategic shift towards diversifying its portfolio beyond CABOMETYX. Ongoing Phase 1 studies for XL309, XB010, and XB628, along with FDA clearance for an IND application for XB371, indicate continued innovation and market leadership [1].

Collaborative partnerships, such as the one with Bristol-Myers Squibb for combination therapies in renal cell carcinoma, also support Exelixis, Inc.'s strategic growth. While the company's potential as an investment is acknowledged, certain AI stocks may offer greater upside potential and carry less downside risk [1].

Given the technical signals and strategic focus, investors may find Exelixis, Inc. an attractive option for further growth. However, as with any investment, it is crucial to conduct thorough research and consider both the technical and fundamental aspects of the company.

References:
[1] https://finance.yahoo.com/news/exelixis-inc-exel-halts-phase-085127677.html